You are here:  > Home Page > Publications

2020 Subscriptions available

Order the next volume of Antiviral Therapy today.

ARV access in resource-poor countries

Highly anticipated special issue with UNAIDS now available

Follow us on Twitter

International Medical Press is now on Twitter. Join our conversation today.


International Medical Press publishes Antiviral Therapy.

Antiviral Therapy is one of the leading journals in virology (2015 ISI impact factor: 2.91). The journal is devoted to publishing high quality articles on the clinical development and use of antiviral agents and vaccines, and the treatment of all viral diseases.




 Journal features

♦ Online submission and manuscript tracking via ScholarOne Manuscripts™
♦ Leading Editorial Boards ensuring high-quality standards
♦ Immediate online publication of all non-commissioned articles
♦ Inclusion in major indexing and abstracting services
♦ Worldwide readership 

Recently published in Antiviral Therapy

Rimsky et al. report long-term resistance to rilpivirine in the ECHO/THRIVE Phase III trials. At 96 weeks, resistance patterns were consistent with 48-week data, and suggest most virological failures and resistance-associated mutations occur during the first year of treatment. Overall, the evidence demonstrates rilpivirine is non-inferior to existing therapies for HIV-infected, treatment-naive patients. Read more here.

The Editorial Office welcomes queries about publishing supplements within the journal. Please visit the Supplements page for more information.

Copyright © 2021 Nucleus Holdings Ltd. Part of Nucleus Global.
Design and Technology by Nucleus Global
Company registration No. 321 0712 (England & Wales). Registered Office address: Admiral House 76-78 Old Street, London EC1V 9AZ.